We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
251
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-250,000
Closed -$14.2M
FLNA
252
CALL
Filana Therapeutics
FLNA
$48.8M
– –
-365,000
Closed -$31.2M
FLNA
253
Filana Therapeutics
FLNA
$48.8M
– –
-5,362
Closed -$458K
STOK icon
254
PUT
Stoke Therapeutics
STOK
$1.8B
– –
-18,000
Closed -$606K
VCEL icon
255
CALL
Vericel Corp
VCEL
$2.35B
– –
-7,900
Closed -$416K
WGS icon
256
GeneDx Holdings
WGS
$1.93B
– –
-6,061
Closed -$2.8M
ZLAB icon
257
CALL
Zai Lab
ZLAB
$2.06B
– –
-1,600
Closed -$284K
TVRD
258
Tvardi Therapeutics
TVRD
$19.7M
– –
-815
Closed -$418K
ITCI
259
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-210,000
Closed -$8.57M
PSTX
260
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-85,837
Closed -$861K
ALPN
261
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-300,454
Closed -$2.7M
BCEL
262
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-250,000
Closed -$2.13M
CCXI
263
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-471,376
Closed -$7.34M
KDMN
264
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-936,615
Closed -$3.63M
CHAQ.U
265
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
– –
-400,000
Closed -$4.37M
CHMA
266
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-90,437
Closed -$428K
ZGNX
267
DELISTED
Zogenix, Inc.
ZGNX
– –
-124,091
Closed -$1.94M
7 8 9 10
11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.